

H3

PATENT
ATTORNEY DOCKET NO. 054160-5060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Tsuneji SUZUKI et al.)	
U.S. Application No.: To Be Assigned)	Group Art Unit: To Be Assigned
Date of National)	
Stage Entry : February 15, 2002)	Examiner: To Be Assigned
Based on PCT/EP00/08011)	
Filed : August 16, 2000)	
For: PHARMACEUTICAL AGENT COMPRISING)	
A BENZAMIDE DERIVATIVE AS ACTIVE)	
INGREDIENT)	

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

A copy of each listed document is attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

An International Search Report citing this document and setting forth the relevance thereof is also enclosed for the Examiner's consideration.

ATTORNEY DOCKET NO. 054160-5060
Page 2


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents do constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP


Lynn E. Eccleston
Reg. No. 35,861

Dated: February 15, 2002
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000